ClinicalTrials.gov
ClinicalTrials.gov Menu

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02384460
Recruitment Status : Completed
First Posted : March 10, 2015
Results First Posted : October 16, 2018
Last Update Posted : October 16, 2018
Sponsor:
Collaborator:
Amicus Therapeutics
Information provided by (Responsible Party):
Scioderm, Inc.

February 13, 2015
March 10, 2015
September 19, 2018
October 16, 2018
October 16, 2018
March 11, 2015
July 5, 2017   (Final data collection date for primary outcome measure)
  • Time To Complete Target Wound Closure Within 3 Months [ Time Frame: From baseline to Month 3 visit ]
    Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. Time to target wound closure was measured from the date of the first administration of the study drug to the date of target wound closure. Participants were censored if they did not have a response within 3 months, or withdrew earlier before the confirmation of their target wound closing. This primary end point displays the mean time to complete target wound closure, analyzed using a Kaplan-Meier approach.
  • The Percentage Of Participants Experiencing Complete Closure Of Their Target Wound Within 3 Months [ Time Frame: From baseline to Month 3 visit ]
    Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. Participants were considered responders if they experienced complete wound closure at the Week 2 or Months 1, 2, or 3 visits. If a target wound was documented to have closed at a given visit, it was considered closed at all subsequent visits. This primary end point displays the percentage of participants from the ITT population who had complete target wound closure by the end of the study period (that is, 3 months). Analysis was performed on participants with post-baseline wound closure data.
Complete closure of the target wound [ Time Frame: Within 2 months ]
Complete target wound closure is defined as skin re-epithelialization without drainage. The primary efficacy analysis will compare the proportion of patients achieving this endpoint within 2 months.
Complete list of historical versions of study NCT02384460 on ClinicalTrials.gov Archive Site
  • Percentage Of Participants Experiencing Complete Closure Of Their Target Wound At Month 1 And Month 2 Visits [ Time Frame: From baseline to Month 1 and Month 2 visits ]
    Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. The percentage of participants who completed target wound closure at the Month 1 and Month 2 study visits is displayed. If a target wound was documented to have closed at a given visit, it was considered closed at all subsequent visits.
  • Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 3 Visit [ Time Frame: Baseline, Month 3 visit ]
    Lesional skin was defined as areas that contained any of the following: blisters, erosions, ulcerations, scabbing, bullae, or eschars, as well as areas that were weeping, sloughing, oozing, crusted, or denuded. BSAI was calculated as a percentage, ranging from 0% to 100%, of affected body surface area, recorded for each defined body region (that is, head/neck, upper limbs, trunk [includes groin], and lower limbs), multiplied by the weighting factor, then summed for all body regions.
  • Change From Baseline In BSAI Of Total Body Wound Burden At Month 3 Visit [ Time Frame: Baseline, Month 3 visit ]
    Total body wound burden was calculated using BSAI. A wound defined as an open area on the skin (that is, epidermal covering disrupted). BSAI was calculated as a percentage, ranging from 0% to 100%, of affected body surface area, recorded for each defined body region (that is, head/neck, upper limbs, lower limbs, trunk [includes groin]), and multiplied by the weighting factor, then summed for all body regions.
  • Change From Baseline In Itching Score At Day 7 [ Time Frame: Baseline, Day 7 ]
    Itching was assessed using the 5-point Itch Man Pruritus Assessment Tool. For participants up to 5 years of age, itching was assessed using caretaker's response and participants 6 years of age and older self-reported their itching assessments based on the following scores: 0=Comfortable, no itch; 1=itches a little, does not interfere with activity; 2=itches more, sometimes interferes with activity; 3=itches a lot, difficult to be still, concentrate; 4=itches most terribly, impossible to sit still or concentrate. Itching scores were categorized into 3 groups based on improvement; Improved or No Itching, Not Improved, and Missing. An itching score reduction from baseline greater than or equal to 1 point on the scale was classed as improved.
  • Change From Baseline In Pain Score At Day 7 [ Time Frame: Baseline, Day 7 ]
    Change in pain assessed at Day 7 compared to baseline was measured using the Face, Legs, Activity, Cry, and Consolability (FLACC) behavioral scale for participants 1 month to 3 years of age. Each of the 5 FLACC categories was scored from 0 to 2, which resulted in a total score between 0 and 10 with 0=Relaxed and comfortable, 1 to 3=Mild discomfort, 4 to 6=Moderate pain, and 7 to 10=Severe discomfort/pain. For participants 4 years of age and older, the "Wong Faces Pain Scale" was used. This scale shows a series of faces ranging from a happy face at 0, which represents "no hurt," to a crying face at 10, which represents "hurts worst". Pain scores were categorized into 3 groups based on improvement: Improved or No Pain, Not Improved, and Missing. A pain score reduction from baseline greater than or equal to 2 points on the scale was classed as improved.
  • Median time to complete target wound closure [ Time Frame: Within 3 months ]
  • Change in lesional skin [ Time Frame: Month 3 ]
    Based on BSA estimates at month 3, compared to baseline
  • Change in itching using Itch Man Pruritus Assessment Tool [ Time Frame: Day 7 ]
    Assessed at Day 7 using Itch Man Pruritus Assessment Tool, compared to baseline
  • Change in pain using "FLACC scale" for patients up to 3 years of age and using "Wrong Faces Pain Scale" for patients 4 years of age and older [ Time Frame: Day 7 ]
    Assessed at Day 7, compared to baseline using the "FLACC scale" for patients up to 3 years of age and for patients 4 years of age and older the "Wong Faces Pain Scale" will be utilized.
Not Provided
  • Estimation of Total Body Wound Burden [ Time Frame: 2 weeks; months 1, 2 and 3 ]
    Assessed at 2 weeks and Months 1, 2 and 3; compared to baseline
  • Change in lesional skin [ Time Frame: week 2; months 1 and 2 ]
    based on BSA estimates, compared to baseline
  • Presence of scarring of healed target wound [ Time Frame: once target wound has healed assessed at day 7 ]
  • Change in itching and pain [ Time Frame: Days 1 to 6; week 2; months 1, 2 and 3 ]
    Assessed at Days 1 to 6, Week 2 and Months 1, 2 and 3; compared to baseline
  • Proportion of patients experiencing target wound closure [ Time Frame: Week 2; Months 1 and 3 ]
 
ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
The aim was to assess the efficacy and safety of SD-101-6.0 cream versus Placebo (SD-101-0.0) cream in the treatment of skin lesions in participants with Epidermolysis Bullosa. Funding Source - United States Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD).
This was a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of SD-101-6.0 cream versus placebo (SD-101-0.0) cream on skin lesions in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz Epidermolysis Bullosa (EB). Epidermolysis Bullosa is a rare group of inherited disorders that typically manifest at birth as blistering and lesion formation on the skin in response to little or no apparent trauma. In this study, SD-101-6.0 cream or placebo (SD-101-0.0) cream was to be applied topically, once a day to the entire body for a period of 90 days. Participants had 1 target wound selected at baseline by the investigator. The selected target wound was required to have been present for at least 21 days. Photographic confirmation of the target wound location was collected at baseline, and the picture saved from the first visit was used to confirm location of the target wound at subsequent visits. The participant returned to the study site for Visit 2 (approximately 14 days from baseline), Visit 3 (approximately 30 days from baseline), Visit 4 (approximately 60 days from baseline), and Visit 5 (approximately 90 days from baseline) to have the target wound assessed for the level of healing. In addition, itching, pain, body surface area, target wound closure, and scarring of healed target wound were assessed at each visit. The ARANZ SilhouetteStar™ was used to measure the target wound at all visits.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Epidermolysis Bullosa
  • Drug: SD-101-6.0 cream
    applied topically once a day for 90 days
    Other Name: SD-101
  • Drug: Placebo (SD-101-0.0) cream
    applied topically once a day for 90 days
    Other Name: placebo
  • Experimental: SD-101-6.0 cream
    SD-101-6.0 cream applied topically, once a day to the entire body for a period of 90 days
    Intervention: Drug: SD-101-6.0 cream
  • Placebo Comparator: Placebo (SD-101-0.0) cream
    SD-101-0.0 (placebo) cream applied topically, once a day to the entire body for a period of 90 days
    Intervention: Drug: Placebo (SD-101-0.0) cream
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
169
130
July 5, 2017
July 5, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Informed Consent form signed by the participant or participant's legal representative; if the participant was under the age of 18 but capable of providing assent, signed assent from the participant.
  • Participant (or caretaker) must have been willing to comply with all protocol requirements.
  • Diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB.
  • Participant must have had 1 target wound (size 10 to 50 cm^2) at study entry.
  • Participants 1 month and older.
  • Target wound must have been present for at least 21 days.

Exclusion Criteria:

  • Participants who did not meet the entry criteria outlined above.
  • Selected target wound did not have clinical evidence of local infection.
  • Use of any investigational drug within the 30 days before enrollment.
  • Use of immunotherapy or cytotoxic chemotherapy within the 60 days before enrollment.
  • Use of systemic or topical steroidal therapy within the 30 days before enrollment. (Inhaled steroids and ophthalmic drops containing steroids were allowed).
  • Use of systemic antibiotics within the 7 days before enrollment.
  • Current or former malignancy.
  • Arterial or venous disorder resulting in ulcerated lesions.
  • Pregnancy or breastfeeding during the study. (A urine pregnancy test was performed at screening and every 30 days until the final visit for female participants of childbearing potential).
  • Females of childbearing potential who were not abstinent and not practicing a medically acceptable method of contraception.
Sexes Eligible for Study: All
1 Month and older   (Child, Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Austria,   France,   Germany,   Israel,   Italy,   Lithuania,   Netherlands,   Poland,   Serbia,   Spain,   United Kingdom,   United States
 
 
NCT02384460
SD-005
2014-002288-14 ( EudraCT Number )
R01-005095-01 ( Other Identifier: Orphan Product Grant )
No
Not Provided
Not Provided
Scioderm, Inc.
Scioderm, Inc.
Amicus Therapeutics
Study Director: Medical Monitor Amicus Therapeutics
Scioderm, Inc.
September 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP